Flynn Daniel Lee 4
4 · Deciphera Pharmaceuticals, Inc. · Filed Jan 19, 2023
Insider Transaction Report
Form 4
Flynn Daniel Lee
Chief Scientific Officer
Transactions
- Sale
Common Stock
2023-01-17$21.24/sh−2,403$51,043→ 43,695 total
Holdings
- 230,435(indirect: By Trust)
Common Stock
- 91,020(indirect: By Trust)
Common Stock
Footnotes (1)
- [F1]This sale was to cover tax liabilities in the vesting of restricted stock.